Dimethandrolone buciclate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dimethandrolone buciclate
Dimethandrolone buciclate.svg
Clinical data
Synonyms CDB-4386A; 7α,11β-Dimethyl-19-nortestosterone 17β-buciclate
Routes of
administration
Intramuscular injection
Drug class Androgen; Anabolic steroid; Androgen ester; Progestogen
Identifiers
Chemical and physical data
Formula C31H48O3
Molar mass 468.7110 g/mol
3D model (JSmol)

Dimethandrolone buciclate (developmental code name CDB-4386A), or dimethandrolone bucyclate, also known as 7α,11β-dimethyl-19-nortestosterone 17β-buciclate, is a synthetic anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was developed by the Contraceptive Development Branch (CDB) of the National Institute of Child Health and Human Development (NICHD) and has not been marketed at this time.[1][2][3][4][5] It is an androgen ester – specifically, the C17β buciclate (4-butylcyclohexane-1-carboxylate) ester of dimethandrolone (7α,11β-dimethyl-19-nortestosterone) – and acts as a prodrug of dimethandrolone in the body.[1][2][3][4][5] Dimethandrolone buciclate is or was under investigation as a potential male contraceptive.[1][2][3][4][5]

See also[edit]

References[edit]

  1. ^ a b c Blye, Richard, and Hyun Kim. "Methods of making and using 7a, 11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a, 11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate." U.S. Patent Application No. 10/260,854.
  2. ^ a b c Blye, Richard, and Hyun Kim. "Method of making and using 7alpha, 11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate." U.S. Patent Application No. 11/040,964.
  3. ^ a b c Blye, Richard P., et al. "Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof." U.S. Patent No. 7,196,074. 27 Mar. 2007.
  4. ^ a b c Blye, Richard P., and Hyun K. Kim. "Method of making and using 7alpha, 11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate." U.S. Patent Application No. 12/184,600.
  5. ^ a b c Brown, A.E.; Sorbera, L.A. (2013). "Therapeutic targets for male contraception". Drugs of the Future. 38 (7): 499. doi:10.1358/dof.2013.038.07.1980494. ISSN 0377-8282.